Evidence map›Paper›PMID 25170444›Full record

ReviewJournal of public health research2012

Analysis of existing international policy evidence in public health genomics: mapping exercise.

Elena V Syurina, Tobias Schulte In den Bäumen, Frans J M Feron, Angela Brand

Abstract readReview
In one paragraph

Review in Journal of public health research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elena V SyurinaDepartment of Social Medicine, School for Public Healh and Primary Care (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maasricht University , the Netherlands ; ; Institute for Public Health Genomics, School for Public Health and Primary Care (CAPHRI), Cluster of Genetics and Cell Biology, Faculty of Health, Madicine and Life Sciences, Maastricht University , the Netherlands.
Tobias Schulte In den BäumenInstitute for Public Health Genomics, School for Public Health and Primary Care (CAPHRI), Cluster of Genetics and Cell Biology, Faculty of Health, Madicine and Life Sciences, Maastricht University , the Netherlands.
Frans J M FeronDepartment of Social Medicine, School for Public Healh and Primary Care (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maasricht University , the Netherlands ;
Angela BrandInstitute for Public Health Genomics, School for Public Health and Primary Care (CAPHRI), Cluster of Genetics and Cell Biology, Faculty of Health, Madicine and Life Sciences, Maastricht University , the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the last decades we have seen a constant growth in the fields of science related to the use of genome-based health information. However, there is a gap between basic science research and the Public Health everyday practice. For a successful introduction of genome-based technologies policy actions on the international level are needed. This work represents the initial stage of the PHGEN II (Public Health Genomics European Network II) project. In order to prepare a base for bridging genomics and Public Health, an inventory study of the existing legislative base dealing with controversies of genome-based knowledge was conducted. The work results in the mapping of the most and the least legislatively covered areas and some preliminary conclusions about the existing gaps. DESIGN AND

methodsThe collection of the evidence-based policies was done through the PHGEN II project. The mapping covered the meta-level (international, European general guidelines). The expert opinion of the partners of the project was required to reflect on and grade the collected evidence.

resultsAN ANALYSIS OF THE EVIDENCE WAS MADE BY THE AREA OF COVERAGE: using the list of important policy areas for successful introduction of genome-based technologies into Public Health and the Public Health Genomics Wheel (originally Public Health Wheel developed by Institute of Medicine).

conclusionsSevere inequalities in coverage of important issues of Public Health Genomics were found. The most attention was paid to clinical utility and clinical validity of the screening and the protection of human subjects. Important areas such as trade agreements, Public Health Genomics literacy, insurance issues, behaviour modification in response to genomics results etc. were paid less attention to. For the successful adoption of new technologies on the Public Health level the focus should be not only on the translation to clinical practice, but the translation from bench to Public Health policy and back. Coherent and consistent coverage of all aspects of the translation of genome based information and technologies is of outmost importance.

Indexed as

genomicslegislationpolicypublic healthpublic health genomicstranslational research

Identifiers

PMID25170444
PMCPMC4140310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.